Which patients (or patient groups) are most associated with sapropterin (BH4) research?
Sapropterin research has mainly centered on people with inherited disorders of tetrahydrobiopterin (BH4) production or use, and on clinical outcomes tied to blood phenylalanine levels and neurodevelopment. The term “patients mainly involved” in this area usually refers to disease cohorts rather than a short list of named individuals.
Key patient groups include people with:
- Phenylketonuria (PKU), including BH4-responsive PKU
Sapropterin has been studied in PKU patients whose phenylalanine levels improve with BH4 supplementation. In practice, clinical trials often enroll children and adults diagnosed with phenylketonuria who meet criteria for “BH4 responsiveness.”
- Hyperphenylalaninemia (HPA)
This includes patients with elevated phenylalanine who may not meet full diagnostic criteria for PKU but still show biochemical response patterns used to evaluate sapropterin.
- Disorders related to BH4 metabolism (BH4-responsive or BH4-related conditions)
Research also includes patient groups where BH4 availability is a limiting factor, such as conditions caused by defects in BH4 synthesis or regeneration pathways. These studies focus on biochemical correction and clinical stabilization.
Are there specific “named patients” you can list?
In most medical literature and regulatory evidence for sapropterin, researchers do not identify a small set of named patients as the primary contributors. Trials and studies typically describe cohorts by diagnosis (for example, BH4-responsive PKU or BH4-related disorders) and by eligibility criteria (age, baseline phenylalanine, response thresholds), rather than naming individuals in the way you might see in a case report series.
What you can look for if you need patient names anyway
If you specifically need named patients, the most likely sources are:
- Case reports describing individual responses to sapropterin (single-patient publications)
- Long-term follow-up papers that sometimes describe participants individually, though often still anonymized or described by baseline characteristics
If you tell me which aspect you mean by “sapropterin research” (PKU trials, BH4 metabolism disorders, or a specific paper/trial), I can narrow the answer to the type of patients involved in that exact line of research and point you to the most relevant study descriptions.
What sapropterin is typically being tested for in those patient cohorts
Sapropterin is used to evaluate whether increasing BH4 improves:
- Blood phenylalanine control in PKU and hyperphenylalaninemia
- Clinical and developmental outcomes in responsive patients
- Metabolic stabilization in BH4-related conditions
Because your question asks about “patients mainly involved,” the most accurate way to answer from standard research framing is by diagnosis cohorts (PKU/HPA and BH4-related disorders), not named individuals.
Sources
No source links were provided in your prompt, and I do not have enough information to cite specific studies or identify named participants reliably without seeing the specific papers you’re referring to.